Southwest Securities released a research report on April 28 stating that Bairen Healthcare (688198.SH) was given a purchase rating. The main reasons for the rating include: 1) rapid growth in performance in 2023, maintaining a high level of gross margin;

Southwest Securities released a research report on April 28 stating that Bairen Healthcare (688198.SH) was given a purchase rating. The main reasons for the rating include: 1) rapid growth in performance in 2023, maintaining a high level of gross margin; 2) achieving high growth in all business lines in 2023; 3) continuing to increase R&D and improve product layout. (Mainichi Keizai Shimbun)

Zhitong FinanceApr 28 09:24

Bairen Healthcare (688198): Strong performance growth and resilience, and the research pipeline continues to be certified

Cow pericardial valves continue to be released, and it is expected that elective surgery will continue to recover. The company achieved operating income of 371 million yuan for the full year of 2023, +25.57% year on year, and net profit of 140 million yuan after excluding share payments, -3.52 million yuan year on year

東方證券Apr 28 00:00

Bairen Medical (688198): Limited expandable valve volume is imminent, high R&D helps product echelon layout

Incident: The company released its 2023 annual report and 2024 quarterly report. In 2023, it achieved revenue of 370 million yuan (+25.6%) and realized net profit of 120 million yuan (+21.1%) to mother. Payment fees excluding shares 29

西南證券Apr 23 00:00

Bank of China Securities released a research report on April 22 stating that it gave Bairen Healthcare (688198.SH) a purchase rating. The main reasons for the rating include: 1) the approval of the first domestic vascular biological supplement, which is e

Bank of China Securities released a research report on April 22 stating that it gave Bairen Healthcare (688198.SH) a purchase rating. The main reasons for the rating include: 1) the approval of the first domestic vascular biological supplement, which is expected to fill the gap in the industry; 2) the broad market space is expected to help the company achieve accelerated growth in performance. (Mainichi Keizai Shimbun)

Zhitong FinanceApr 22 20:32

Bairen Healthcare (688198.SH): Net profit of 8.319,800 yuan in the first quarter decreased by 28.88% year-on-year

Gelonghui, April 22丨Bairen Healthcare (688198.SH) released its report for the first quarter of 2024. Operating revenue for the reporting period was 76.265,200 yuan, up 17.53% year on year; net profit attributable to shareholders of listed companies was 8.3198 million yuan, down 28.88% year on year; net profit attributable to shareholders of listed companies after deducting non-recurring profit and loss was 6.3778 million yuan, down 29.26% year on year; basic earnings per share were 0.06 yuan.

Gelonghui FinanceApr 22 15:54

Express News | Bairen Medical: Vascular biological supplement products approved for registration

BreakingsApr 19 15:36